Jaguar Health, Inc. (JAGX)
- Previous Close
0.1771 - Open
0.1621 - Bid 0.1669 x 8000
- Ask 0.1706 x 13600
- Day's Range
0.1535 - 0.1723 - 52 Week Range
0.0510 - 1.2200 - Volume
20,098,606 - Avg. Volume
59,345,711 - Market Cap (intraday)
48.547M - Beta (5Y Monthly) 1.38
- PE Ratio (TTM)
-- - EPS (TTM)
-1.7900 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.
jaguar.healthRecent News: JAGX
Performance Overview: JAGX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: JAGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: JAGX
Valuation Measures
Market Cap
50.87M
Enterprise Value
81.50M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.42
Price/Book (mrq)
10.25
Enterprise Value/Revenue
8.35
Enterprise Value/EBITDA
-2.46
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-43.17%
Return on Equity (ttm)
-2,366.62%
Revenue (ttm)
9.76M
Net Income Avi to Common (ttm)
-41.3M
Diluted EPS (ttm)
-1.7900
Balance Sheet and Cash Flow
Total Cash (mrq)
6.47M
Total Debt/Equity (mrq)
757.48%
Levered Free Cash Flow (ttm)
-17.15M